Stratification of patients according to the MASLD development after 24 months demonstrated that the MASLD-T2DM group had significantly lower adiponectin (38.94±1.17 vs. 42.14±1.46 (p<0.001)), A/R index (2.65 (2.58-2.68) vs. 2.84 (2.81-2.87) (p<0.001)), and higher resistin (266.71 (261.15-271.81) vs. 240.12 (233.06-245.75) (p<0.001)) compared to the non-MASLD-T2DM group (Table 2). The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.